Investor Atlas Venture Fund XI, L.P.
13D/G Filings

This page shows a list of all the recent 13D/G filings made by Atlas Venture Fund XI, L.P. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).

When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.

Date Form Target Prev
Shares
Current
Shares
Change
(Percent)
Ownership
(Percent)
Change
(Percent)
2025-02-18 13D SION / Sionna Therapeutics, Inc.
2024-11-14 13G/A DYN / Dyne Therapeutics, Inc. 7,342,083 5,714,057
2024-11-14 13G/A DAWN / Day One Biopharmaceuticals, Inc. 6,047,818 4,869,681
2024-11-14 13G/A XLO / Xilio Therapeutics, Inc. 2,023,402 0
2024-11-05 13D/A THRD / Third Harmonic Bio, Inc. 9,808,190
2024-02-09 13G/A DYN / Dyne Therapeutics, Inc. 7,326,117 7,342,083
2024-02-09 13G/A DAWN / Day One Biopharmaceuticals, Inc. 6,008,534 6,047,818
2023-11-13 13D KRRO / Korro Bio, Inc. 942,075
2023-02-14 13G/A AKRO / Akero Therapeutics, Inc. 1,963,529 467,529
2023-02-14 13G/A DYN / Dyne Therapeutics, Inc. 7,326,117 7,326,117
2023-02-14 13G/A DAWN / Day One Biopharmaceuticals, Inc. 7,210,242 6,008,534
2022-09-29 13D / Third Harmonic Bio, Inc. 10,313,763
2022-02-11 13G/A AKRO / Akero Therapeutics, Inc. 2,206,412 1,963,529
2022-02-11 13G DAWN / Day One Biopharmaceuticals, Inc. 7,210,242
2022-02-11 13G/A DYNE / Dyntek Inc 8,140,130 7,326,117
2021-11-05 13G XLO / Xilio Therapeutics, Inc. 2,023,402
2021-02-16 13G/A AKRO / Akero Therapeutics, Inc. 2,206,412
2021-02-16 13G DYNE / Dyntek Inc 8,140,130
2020-02-13 13G MGTA / Magenta Therapeutics Inc 2,706,412